• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form EFFECT filed by Zynerba Pharmaceuticals Inc.

    10/12/23 12:15:05 AM ET
    $ZYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ZYNE alert in real time by email
    Notice of Effectiveness
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    Notice of Effectiveness
    Effectiveness Date: October 11, 2023
    Accession Number: 0001140361-23-047719
    Submission Type: POS AM
    CIK: 0001621443
    Company Name: Zynerba Pharmaceuticals, Inc.
    File Number: 333-264966
    Get the next $ZYNE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ZYNE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ZYNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Zynerba Pharmaceuticals with a new price target

      Roth Capital reiterated coverage of Zynerba Pharmaceuticals with a rating of Buy and set a new price target of $7.25 from $8.00 previously

      3/10/21 4:21:24 PM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity resumed coverage on Zynerba Pharmaceuticals with a new price target

      Canaccord Genuity resumed coverage of Zynerba Pharmaceuticals with a rating of Buy and set a new price target of $18.00

      2/5/21 4:18:35 AM ET
      $ZYNE
      Biotechnology: Pharmaceutical Preparations
      Health Care